Referral List

providing mental health &
substance abuse services for
the people of Alameda County ...

Print This Page

Click here to send us your feedback.

Last Updated: 01/29/2008

Evaluation of Atypical Antipsychotic Medication Assistance Programs Printer Friendly Version

Inside This Section
[ Percentage Approved Applications per Atypical Antipsychotic ][ # Rxs/Approved Application ][ Total Cost Savings per Atypical Antipsychotic ]

Objective

To determine the effectiveness of atypical antipsychotic (olanzapine, quetiapine, risperidone) PAPs
To contrast their acceptance percentage, approval period and total cost savings incurred.

Methods

N=320 indigent patients receiving an atypical antipsychotics
Multi-center study (12 different sites) throughout Alameda Co., California
1 year evaluation period (7/1/2000 – 6/30/2001)

Results

Antipsychotic	Approval Rate	Total Rxs	Mean Rxs/app	Total Savings
Olanzapine	65%	614	5.8	$ 157,798
Quetiapine	61%	61	2.4	$ 13,237
Risperidone	54%	176	2.8	$ 30,096

Evaluation

Favorable program characteristics:

provider eligibility determination
bulk medication shipment
long (6-9 month) program eligibility period
email interface

65% of study patients achieved MediCaid (MediCal) eligibility at 12 months,

Olanzapine program resulted in the greatest success as measured by:

approval rate, total prescriptions,
mean prescriptions per application and
total cost savings.

Conclusions

None of the programs ideal for use by County system

Programs need to streamline application process, provide bulk meds, and have longer eligibility periods

BHCS MIA 2001: Percentage Approved Applications per Atypical Antipsychotic

top

BHCS MIA 2001: # Rxs/Approved Application

top

BHCS MIA 2001: Total Cost Savings per Atypical Antipsychotic

top

Methods

Results

Antipsychotic

Approval Rate

Total Rxs

Evaluation

Conclusions